Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients

References

• Darke S, Swift W, Hall W, Ross M. Drug use, HIV risk-taking and psychosocial correlates of benzodiazepine use among methadone maintenance clients. Drug Alcohol Depend 1993;34:67–70.
   PubMed Web of Science ®Google Scholar
• Iguchi MY, Handelsman L, Bickel WK, Griffiths RR. Benzodiazepine and sedative use/abuse by methadone maintenance clients. Drug Alcohol Depend 1993;32:257–266.
   PubMed Web of Science ®Google Scholar
• Kidorf M, Brooner RK, King VL, Chutuape MA, Stitzer ML. Concurrent validity of cocaine and sedative dependence diagnoses in opioid-dependent outpatients. Drug Alcohol Depend 1996;42:117–123.
   PubMed Web of Science ®Google Scholar
• Bleich A, Gelkopf M, Schmidt V, Hayward R, Bodner G, Adelson M. Correlates of benzodiazepine abuse in methadone maintenance treatment. A 1 year prospective study in an Israeli clinic. Addiction 1999;94:1533–1540.
   Google Scholar
• Gelkopf M, Bleich A, Hayward R, Bodner G, Adelson M. Characteristics of benzodiazepine abuse in methadone maintenance treatment patients: a 1 year prospective study in an Isra eli clinic. Drug Alcohol Depend 1999;55:63–68.
   PubMed Web of Science ®Google Scholar
• Bleich A, Gelkopf M, Weizman T, Adelson M. Benzodiazepine abuse in a methadone maintenance treatment clinic in Israel: characteristics and a pharmacotherapeutic approach. Isr J Psychiatry Relat Sci 2002:39:104–112.
   Web of Science ®Google Scholar
• Specka M, Bonnet U, Heilmann M, Schifano F, Scherbaum N. Longitudinal patterns of benzodiazepine consumption in a German cohort of methadone maintenance treatment patients. Hum Psychopharmacol 2011;26:404–411.
   PubMed Web of Science ®Google Scholar
• Chen KW, Berger CC, Forde DP, D’Adamo C, Weintraub E, Gandhi D. Benzodiazepine use and misuse among patients in a methadone program. BMC Psychiatry 2011;11:90.
   PubMed Web of Science ®Google Scholar
• Condelli WS, Dunteman GH. Exposure to methadone programs and heroin use. Am J Drug Alcohol Abuse 1993;19:65–78.
   PubMed Web of Science ®Google Scholar
• McCarthy JE, Siney C, Shaw NJ, Ruben SM. Outcome predictors in pregnant opiate and polydrug users. Eur J Pediatr 1999;158:748–749.
   PubMed Web of Science ®Google Scholar
• Caplehorn JR, Dalton MS, Haldar F, Petrenas AM, Nisbet JG. Methadone maintenance and addicts’ risk of fatal heroin overdose. Subst Use Misuse 1996;31:177–196.
   PubMed Web of Science ®Google Scholar
• Ernst E, Bartu A, Popescu A, Ileutt KF, Hansson R, Plumley N. Methadone-related deaths in Western Australia 1993-99, Aust N Z J Public Health 2002: 26: 364–370.
   PubMed Web of Science ®Google Scholar
• Caplehorn JR, Drummer OH. Fatal methadone toxicity: signs and circumstances, and the role of benzodiazepines. Aust N Z J Public Health 2002;26:358–362; discussion 362–353.
   Google Scholar
• Brands B, Blake J, Marsh DC, Sproule B, Jeyapalan R, Li S. The impact of benzodiazepine use on methadone maintenance treatment outcomes. J Addict Dis 2008;27:37–48.
   PubMed Web of Science ®Google Scholar
• Eiroa-Orosa FJ, Haasen C, Verthein U, Dilg C, Schafer I, Reimer J. Benzodiazepine use among patients in heroin-assisted vs. methadone maintenance treatment: findings of the German randomized controlled trial. Drug Alcohol Depend 2010;112:226–233.
   Google Scholar
• Schoch P, Mohler H. Purified benzodiazepine receptor retains modulation by GABA. Eur J Pharmacol 1983;95:323–324.
   PubMed Web of Science ®Google Scholar
• Schofield PR, Darlison MG, Fujita N, Burt DR, Stephenson FA, Rodriguez H, et al. Sequence and functional expression of the GABA A receptor shows a ligand-gated receptor super-family. Nature 1987;328:221–227.
   PubMed Web of Science ®Google Scholar
• Wafford KA. GABAA receptor subtypes: any clues to the mechanism of benzodiazepine dependence? Curr Opinion Pharmacol 2005;5:47–52.
   PubMed Web of Science ®Google Scholar
• Allison C, Pratt JA. Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence. Pharmacol Therapeut 2003;98:171–195.
   PubMed Web of Science ®Google Scholar
• Xiang K, Tietz EI. Benzodiazepine-induced hippocampal CA1 neuron alpha-amino-3-hydroxy-5-methylisoxasole-4-propionic acid (AMPA) receptor plasticity linked to severity of withdrawal anxiety: differential role of voltage-gated calcium channels and N-methyl-D-aspartic acid receptors. Behavioural Pharmacol 2007;18:447–460.
   PubMed Web of Science ®Google Scholar
• Song J, Shen G, Greenfield LJ Jr, Tietz EI. Benzodiazepine withdrawal-induced glutamatergic plasticity involves up-regulation of GluR1-containing alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors in Hippocampal CA1 neurons. J Pharmacol Exp Ther 2007;322:569–581.
   PubMed Web of Science ®Google Scholar
• Heberlein A, Bleich S, Kornhuber J, Hillemacher T. Neuroendocrine pathways in benzodiazepine dependence: new targets for research and therapy. Hum Psychopharmacol 2008;23:171–181.
   PubMed Web of Science ®Google Scholar
• Nardi AE, Freire RC, Valenca AM, Amrein R, de Cerqueira AC, Lopes FL, et al. Tapering clonazepam in patients with panic disorder after at least 3 years of treatment. J Clin Psychopharmacol 2010;30:290–293.
   PubMed Web of Science ®Google Scholar
• Denis C, Fatseas M, Lavie E, Auriacombe M. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst Rev 2006;3:CD005194.
   Google Scholar
• Cantopher T, Olivieri S, Cleave N, Edwards JG. Chronic benzodiazepine dependence. A comparative study of abrupt withdrawal under propranolol cover versus gradual withdrawal. Br J Psychiatry 1990;156:406–411.
   Google Scholar
• Hallstrom C, Crouch G, Robson M, Shine P. The treatment of tranquilizer dependence by propranolol. Postgrad Med J 1988;64(Suppl. 2):40–44.
   PubMed Web of Science ®Google Scholar
• Lader M, Olajide D. A comparison of buspirone and placebo in relieving benzodiazepine withdrawal symptoms. J Clin Psychopharmacol 1987;7:11–15.
   PubMed Web of Science ®Google Scholar
• Schweizer E, Case WG, Garcia-Espana F, Greenblatt DJ, Rickels K. Progesterone co-administration in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal severity and taper outcome. Psychopharmacology (Berl) 1995;117:424–429.
   PubMed Web of Science ®Google Scholar
• Lemoine P, Touchon J, Billardon M. [Comparison of 6 different methods for lorazepam withdrawal. A controlled study, hydroxyzine versus placebo]. L’Encephale 1997;23:290–299.
   PubMed Web of Science ®Google Scholar
• Schweizer E, Rickels K, Case WG, Greenblatt DJ. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome. Arch Gen Psychiatry 1991;48:448–452.
   PubMed Web of Science ®Google Scholar
• Rickels K, Schweizer E, Garcia Espana F, Case G, DeMartinis N, Greenblatt D. Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome. Psychopharmacology (Berl) 1999;141:1–5.
   PubMed Web of Science ®Google Scholar
• Lemoine P, Kermadi I, Garcia-Acosta S, Garay RP, Dib M. Double-blind, comparative study of cyamemazine vs. bromazepam in the benzodiazepine withdrawal syndrome. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:131–137.
   PubMed Web of Science ®Google Scholar
• Hood S, O’Neil G, Hulse G. The role of flumazenil in the treatment of benzodiazepine dependence: physiological and psychological profiles. J Psychopharmacol 2009;23:401–409.
   PubMed Web of Science ®Google Scholar
• Lugoboni F, Faccini M, Quaglio GL, Albiero A, Casari R, Pajusco B. Intravenous flumazenil infusion to treat benzodiazepine dependence should be performed in the inpatient clinical setting for high risk of seizure. J Psychopharmacol 2011;25:848–849.
   PubMed Web of Science ®Google Scholar
• Weizman T, Gelkopf M, Melamed Y, Adelson M, Bleich A. Treatment of benzodiazepine dependence in methadone maintenance treatment patients: a comparison of two therapeutic modalities and the role of psychiatric comorbidity. Aust N Z J Psychiatry 2003;37:458–463.
   PubMed Web of Science ®Google Scholar
• Stitzer M, Bigelow G, Liebson I. Contingent reinforcement of benzodiazepine-free urines from methadone maintenance patients. NIDA Res Monogr 1982;41:282–287.
   PubMedGoogle Scholar
• Stitzer ML, Iguchi MY, Felch LJ. Contingent take-home incentive: effects on drug use of methadone maintenance patients. J Consult Clin Psychol 1992;60:927–934.
   PubMed Web of Science ®Google Scholar
• Chutuape MA, Silverman K, Stitzer M. Contingent reinforcement sustains post-detoxification abstinence from multiple drugs: a preliminary study with methadone patients. Drug Alcohol Depend 1999;54:69–81.
   PubMed Web of Science ®Google Scholar
• McDuff DR, Schwartz RP, Tommasello A, Tiegel S, Donovan T, Johnson JL. Outpatient benzodiazepine detoxification procedure for methadone patients. J Subst Abuse Treat 1993;10:297–302.
   PubMed Web of Science ®Google Scholar
• Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998;29:233–249.
   PubMed Web of Science ®Google Scholar
• Maneuf YP, Gonzalez MI, Sutton KS, Chung FZ, Pinnock RD, Lee K. Cellular and molecular action of the putative GABA-mimetic, gabapentin. Cell Mol Life Sci 2003;60:742–750.
   PubMed Web of Science ®Google Scholar
• Errante LD, Williamson A, Spencer DD, Petroff OA. Gabapentin and vigabatrin increase GABA in the human neocortical slice. Epilepsy Res 2002;49:203–210.
   PubMed Web of Science ®Google Scholar
• Petroff OA, Rothman DL, Behar KL, Lamoureux D, Mattson RH. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Annals Neurology 1996;39:95–99.
   PubMed Web of Science ®Google Scholar
• Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biolog Chem 1996;271:5768–5776.
   PubMed Web of Science ®Google Scholar
• Wang M, Offord J, Oxender DL, Su TZ. Structural requirement of the calcium-channel subunit alpha2delta for gabapentin binding. Biochem J 1999;342(Pt 2):313–320.
   PubMed Web of Science ®Google Scholar
• Marais E, Klugbauer N, Hofmann F. Calcium channel alpha(2)delta subunits-structure and Gabapentin binding. Mol Pharmacol 2001:59:1243–1248.
   Web of Science ®Google Scholar
• Stefani A, Spadoni F, Bernardi G. Gabapentin inhibits calcium currents in isolated rat brain neurons. Neuropharmacology 1998;37:83–91.
   PubMed Web of Science ®Google Scholar
• Alden KJ, Garcia J. Differential effect of gabapentin on neuronal and muscle calcium currents. J Pharmacol Exp Ther 2001;297:727–735.
   PubMed Web of Science ®Google Scholar
• Sutton KG, Martin DJ, Pinnock RD, Lee K, Scott RH. Gabapentin inhibits high-threshold calcium channel currents in cultured rat dorsal root ganglion neurones. Br J Pharmacol 2002;135:257–265.
   PubMed Web of Science ®Google Scholar
• Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opinion Pharmacol 2006;6:108–113.
   PubMed Web of Science ®Google Scholar
• Cheng JK, Chiou LC. Mechanisms of the antinociceptive action of gabapentin. J Pharmacolog Sci 2006;100:471–486.
   PubMed Web of Science ®Google Scholar
• Beydoun A, Uthman BM, Sackellares JC. Gabapentin: pharmacokinetics, efficacy, and safety. Clin Neuropharmacol 1995;18:469–481.
   PubMed Web of Science ®Google Scholar
• Wang PW, Ketter TA. Pharmacokinetics of mood stabilizers and new anticonvulsants. Psychopharmacol Bull 2002;36:44–66.
   PubMedGoogle Scholar
• Beydoun A, Fakhoury T, Nasreddine W, Abou-Khalil B. Conversion to high dose gabapentin monotherapy in patients with medically refractory partial epilepsy. Epilepsia 1998;39:188–193.
   PubMed Web of Science ®Google Scholar
• McLean MJ, Morrell MJ, Willmore LJ, Privitera MD, Faught RE, Holmes GL, et al. Safety and tolerability of gabapentin as adjunctive therapy in a large, multicenter study. Epilepsia 1999;40:965–972.
   PubMed Web of Science ®Google Scholar
• Bergey GK, Morris HH, Rosenfeld W, Blume WT, Penovich PE, Morrell MJ, et al. Gabapentin monotherapy: I. An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 88/89. Neurology 1997;49:739–745.
   PubMed Web of Science ®Google Scholar
• Leach JP, Girvan J, Paul A, Brodie MJ. Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. J Neurol Neurosurg Psychiatry 1997;62:372–376.
   PubMed Web of Science ®Google Scholar
• Dodrill CB, Arnett JL, Hayes AG, Garofalo EA, Greeley CA, Greiner MJ, et al. Cognitive abilities and adjustment with gabapentin: results of a multisite study. Epilepsy Res 1999;35:109–121.
   PubMed Web of Science ®Google Scholar
• Meador KJ, Loring DW, Ray PG, Murro AM, King DW, Nichols ME, et al. Differential cognitive effects of carbamazepine and gabapentin. Epilepsia 1999;40:1279–1285.
   PubMed Web of Science ®Google Scholar
• Salinsky MC, Binder LM, Oken BS, Storzbach D, Aron CR, Dodrill CB. Effects of gabapentin and carbamazepine on the EEG and cognition in healthy volunteers. Epilepsia 2002;43482–490.
   Google Scholar
• Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999;19:341–348.
   PubMed Web of Science ®Google Scholar
• Pande AC, Pollack MH, Crockatt J, Greiner M, Chouinard G, Lydiard RB, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000;20:467–471.
   PubMed Web of Science ®Google Scholar
• Karam-Hage M, Brower KJ. Gabapentin treatment for insomnia associated with alcohol dependence. Am J Psychiatry 2000;157:151.
   PubMed Web of Science ®Google Scholar
• Brower KJ, Myra Kim H, Strobbe S, Karam-Hage MA, Consens F, Zucker RA. A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res 2008;32:1429–1438.
   PubMed Web of Science ®Google Scholar
• Anton RF, Myrick H, Wright TM, Latham PK, Baros AM, Waid LR, et al. Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry 2011;168:709–717.
   PubMed Web of Science ®Google Scholar
• Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Internal Med 2014;174:70–77.
   PubMed Web of Science ®Google Scholar
• Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007;68:1691–1700.
   PubMed Web of Science ®Google Scholar
• Mason BJ, Crean R, Goodell V, Light JM, Quello S, Shadan F, et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology 2012;37:1689–1698.
   PubMed Web of Science ®Google Scholar
• Carroll KM, Nuro K. Compliance enhancement: a manual for the psychopharmacology of drug abuse and dependence. West Haven, CT: Yale University Psychotherapy Development Center Training Series No 4; 1999.
   Google Scholar
• Busto UE, Sykora K, Sellers EM. A clinical scale to assess benzodiazepine withdrawal. J Clin Psychopharmacol 1989;9:412–416.
   PubMed Web of Science ®Google Scholar